Plas-free is an innovative medical company developing a unique device, that can prevent massive bleeding which may ultimately result in death.
Currently, there are limited effective solutions to treat excessive bleeding. According to the National Trauma In
stitute (NTI) over 192,000 patients die every year in the US due to blood loss associated with injury. Most of treatments are focussed on enhancing coagulation. Today there is no no effective treatments that addresses hyperfibrinolysis. Fibrinolysis is responsible for fibrin breakdown. Hyperfibrinolysis occurs when fibrinolytic activity is potentially greater than fibrin formation such that clot integrity is threatened. Today, it is known that 57% of trauma patients and 60% of cirrhotic patients present hyperfibrinolysis, thus enhancing coagulation has poor outcome for these patients.
Plas-free's device effectively removes plasminogen, a specific protein related to the fibrinolytic system, from blood plasma and by doing so prevents massive bleeding. Pre-clinical trials in a murine model system demonstrated a significant reduction in blood loss in animals treated with our unique filtration system. The company is aiming to complete pre-clinical trials, including in pigs, in Q1 of 2018. In addition, the company is designing a clinical trial that is planned for Q3 of 2018.
The market for plasma treating bleeding disorders was estimated at approximately $3.20 billion in 2016 and growing at a CAGR of around 4.0%.
We at Plas-free are offering an innovative device targeting a huge market with a major unmet need.
Our management team:
- Prof. Abed Elrauf Hijazi, M.D – Founder & CSO
- Zeev Dvashi, PhD– CEO
- Nizar Mishael - CFO
- Zohar Gendler – Chairman of the board
Haemostasis, Medical Device, Coagulation
Nazareth, Nazareth, Israel